Key result
Continuous trastuzumab treatment for more than 9 years resulted in complete remission without any significant cardiac toxicity in a woman with metastatic breast cancer.
Why the study?
Does continuous long-term trastuzumab treatment cause cardiac toxicity in metastatic breast cancer?
Does continuous long-term trastuzumab treatment cause cardiac toxicity in metastatic breast cancer?
Long-term continuous trastuzumab therapy may be administered without significant cardiac toxicity in some patients with metastatic breast cancer.
Supports safe long-term trastuzumab in select metastatic breast cancer patients; leaves open need for prospective validation.
The main concern of long-term use of trastuzumab remains its association with potential cardiac side effects. Although these side effects are real, they are probably overemphasized. We report the case of a woman with metastatic breast cancer, who is currently in complete remission, and who received trastuzumab continuously for more than 9 years, without any significant cardiac toxicity.
No takes yet. Share an insight, caveat, or question.
Paul et al. (2014) studied this question. Continuous trastuzumab treatment for more than 9 years resulted in complete remission without any significant cardiac toxicity in a woman with metastatic breast cancer.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: